Human Tissue Factor Pathway Inhibitor Fused to CD4 Binds both FXa and TF/FVIIa at the Cell Surface

No abstract is available for this paper.

• Publication year

  1997

• Venue

  Thrombosis and Haemostasis

• Publication date

  1997-12-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1055/s-0038-1665439PMID 9423800
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Tissue factor pathway inhibitor.

  1999cited by this paper
• Antigen recognition.

  1999cited by this paper
• Delayed Xenograft Rejection

  1997cited by this paper
• Morphology of hDAF (CD55) transgenic pig kidneys following ex-vivo hemoperfusion with human blood.

  1997cited by this paper
• Binding of tissue factor pathway inhibitor to cultured endothelial cells-influence of glycosaminoglycans.

  1996cited by this paper
• Delayed xenograft rejection.

  1996cited by this paper
• Depletion of Intravascular Pools of Tissue Factor Pathway Inhibitor (TFPI) during Repeated or Continuous Intravenous Infusion of Heparin in Man

  1996cited by this paper
• Ligand-induced protease receptor translocation into caveolae: a mechanism for regulating cell surface proteolysis of the tissue factor- dependent coagulation pathway

  1996cited by this paper
• Prevention of Microvascular Thrombosis by Topical Application of Recombinant Tissue Factor Pathway Inhibitor

  1996cited by this paper
• Transplantation of discordant xenografts: a challenge revisited.

  1996cited by this paper
• Human Ryudocan from Endothelium-like Cells Binds Basic Fibroblast Growth Factor, Midkine, and Tissue Factor Pathway Inhibitor (*)

  1996cited by this paper
• Inhibitory properties of separate recombinant Kunitz-type-protease-inhibitor domains from tissue-factor-pathway inhibitor.

  1996cited by this paper
• Prevention of spinal cord injury after transient aortic clamping with tissue factor pathway inhibitor.

  1996cited by this paper
• Regulation of the extrinsic pathway system in health and disease: the role of factor VIIa and tissue factor pathway inhibitor.

  1995cited by this paper
• Human complement regulatory proteins protect swine-to-primate cardiac xenografts from humoral injury

  1995cited by this paper
• Tissue Factor Pathway Inhibitor

  1995cited by this paper
• Inherited Factor VII Deficiency: Genetics and Molecular Pathology

  1995cited by this paper
• Xenotransplantation.

  1995cited by this paper
• Tissue factor pathway.

  1994cited by this paper
• High-level production of human blood coagulation factors VII and XI using a new mammalian expression vector.

  1994cited by this paper
• Structural biology of tissue factor, the initiator of thrombogenesis in vivo 1

  1994cited by this paper
• Tissue factor pathway.

  1994cited by this paper
• Identification of the factor VIIa binding site on tissue factor by homologous loop swap and alanine scanning mutagenesis.

  1994cited by this paper
• Pharmacokinetics of Full Length and Two-Domain Tissue Factor Pathway Inhibitor in Combination with Heparin in Rabbits

  1993cited by this paper
• Characterization of human tissue factor pathway inhibitor variants expressed in Saccharomyces cerevisiae.

  1993cited by this paper
• Crystal structure of domains 3 and 4 of rat CD4: relation to the NH2-terminal domains.

  1993cited by this paper
• Inhibitory properties of full-length and truncated recombinant tissue factor pathway inhibitor (TFPI). Evidence that the third Kunitz-type domain of TFPI is not essential for the inhibition of factor VIIa-tissue factor complexes on cell surfaces.

  1993cited by this paper
• The effect of two-domain tissue factor pathway inhibitor on endotoxin-induced disseminated intravascular coagulation in rabbits.

  1993cited by this paper
• A chimeric poliovirus/CD4 receptor confers susceptibility to poliovirus on mouse cells

  1992cited by this paper
• Mechanisms of binding of recombinant extrinsic pathway inhibitor (rEPI) to cultured cell surfaces. Evidence that rEPI can bind to and inhibit factor VIIa-tissue factor complexes in the absence of factor Xa.

  1992cited by this paper
• Release of heparan sulfate from endothelial cells. Implications for pathogenesis of hyperacute rejection

  1990cited by this paper
• Functional significance of the Kunitz-type inhibitory domains of lipoprotein-associated coagulation inhibitor

  1989cited by this paper
• Purification and characterization of the lipoprotein-associated coagulation inhibitor from human plasma.

  1989cited by this paper
• Platelets secrete a coagulation inhibitor functionally and antigenically similar to the lipoprotein associated coagulation inhibitor.

  1988cited by this paper
• Heparin induces release of extrinsic coagulation pathway inhibitor (EPI).

  1988cited by this paper
• The lipoprotein-associated coagulation inhibitor that inhibits the factor VII-tissue factor complex also inhibits factor Xa: insight into its possible mechanism of action.

  1988cited by this paper
• The lipoprotein-associated coagulation inhibitor that inhibits the factor VII-tissue factor complex also inhibits factor Xa: insight into its possible mechanism of action

  1988cited by this paper
• Structural model of HLA-DR1 restricted T cell antigen recognition.

  1988cited by this paper
• Cloning and characterization of a cDNA coding for the lipoprotein-associated coagulation inhibitor shows that it consists of three tandem Kunitz-type inhibitory domains.

  1988cited by this paper
• A human beta-actin expression vector system directs high-level accumulation of antisense transcripts.

  1987cited by this paper
• The isolation and nucleotide sequence of a cDNA encoding the T cell surface protein T4: a new member of the immunoglobulin gene family.

  1985cited by this paper
• Expression of H-2Dd and H-2Ld mouse major histocompatibility antigen genes in L cells after DNA-mediated gene transfer.

  1983cited by this paper
• Separation of functional subsets of human T cells by a monoclonal antibody.

  1979cited by this paper

• Neointimal hyperplasia after endoluminal injury in mice is dependent on tissue factor- and angiopoietin-2 dependent interferon gamma production by fibrocytes and macrophages

  2024cites this paper
• Effects of human TFPI and CD47 expression and selectin and integrin inhibition during GalTKO.hCD46 pig lung perfusion with human blood

  2022cites this paper
• Glucose metabolism in pigs expressing human genes under an insulin promoter

  2015cites this paper
• “Islet equivalent” stem cells and diabetes

  2013cites this paper
• Characterization of transgenic pigs that express human decay accelerating factor and cell membrane-tethered human tissue factor pathway inhibitor.

  2011cites this paper
• The role of donor versus recipient tissue factor in coagulopathy during pig-to-primate xenotransplantation.

  2010cites this paper
• Atorvastatin or transgenic expression of TFPI inhibits coagulation initiated by anti‐nonGal IgG binding to porcine aortic endothelial cells

  2010cites this paper
• Complement regulation in the GalT KO era

  2010cites this paper
• Critical roles for thrombin in acute and chronic inflammation

  2009cites this paper
• Tissue factor pathway inhibitor: structure, biology and involvement in disease

  2006cites this paper
• Postinjury vascular intimal hyperplasia in mice is completely inhibited by CD34+ bone marrow‐derived progenitor cells expressing membrane‐tethered anticoagulant fusion proteins

  2006cites this paper
• Endothelial cell protection in xenotransplantation: looking after a key player in rejection

  2006cites this paper
• Microcoagulation processes after xenotransplantation

  2005cites this paper
• Complete Inhibition of Acute Humoral Rejection Using Regulated Expression of Membrane‐tethered Anticoagulants on Xenograft Endothelium

  2004cites this paper
• Inhibition of intravascular thrombosis in murine endotoxemia by targeted expression of hirudin and tissue factor pathway inhibitor analogs to activated endothelium.

  2004cites this paper
• Overexpression of glycosyl phosphatidylinositol-anchored tissue factor pathway inhibitor-1 inhibits tissue factor activity

  2003cites this paper
• Human thrombin and FXa mediate porcine endothelial cell activation; modulation by expression of TFPI‐CD4 and hirudin‐CD4 fusion proteins

  2001cites this paper
• Regulated endothelial cell expression of novel anticoagulants: a strategy for the prevention and therapy of intravascular thrombosis.

  2000cites this paper
• Biomimetic transport and rational drug delivery.

  2000cites this paper
• Regulated inhibition of coagulation by porcine endothelial cells expressing P-selectin-tagged hirudin and tissue factor pathway inhibitor fusion proteins.

  1999cites this paper
• Inhibition of tissue factor-dependent and -independent coagulation by cell surface expression of novel anticoagulant fusion proteins.

  1999cites this paper
• Proteines hybrides anticoagulantes ancrees dans des membranes cellulaires

  1998cites this paper
• Expression of hirudin fusion proteins in mammalian cells: a strategy for prevention of intravascular thrombosis.

  1998cites this paper